What is a “bimosimluar” Cosentyx?
Cosentyx is the brand name for secukinumab, an IL‑17A inhibitor used for inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. A “bimosimluar” (biosimilar) to Cosentyx would be a biosimilar version of secukinumab designed to work the same way, with the same target and similar clinical effects, under regulatory biosimilar pathways.
Is there a biosimilar to Cosentyx approved yet?
The key practical issue is whether any regulator has approved a secukinumab biosimilar under an approved product name in the market you care about (for example, US vs EU vs specific countries). Approval is product- and country-specific, because biosimilars are authorized separately by regulator and with their own labeling.
If you tell me your country (or the market you’re interested in), I can narrow down which secukinumab biosimilars are actually approved there and what their names are.
How does a secukinumab biosimilar work compared with Cosentyx?
Both Cosentyx and its biosimilars are built to target IL‑17A, aiming to reduce the inflammatory signaling that drives diseases like psoriasis and related spondyloarthritis conditions. Biosimilars are expected to be highly similar to the reference product in structure, function, and clinical performance, even though they are not identical biologics.
What determines whether patients can switch to a Cosentyx biosimilar?
Common real-world drivers include:
- Regulatory approval and labeling in your country (what indications are covered)
- Prescriber comfort and clinic switching policies
- Pharmacy substitution rules (varies by country)
- Patient history (treatment response, prior biologic failures)
- Safety monitoring after switching (any new adverse effects or loss of response)
If you share whether you’re asking as a patient, prescriber, or researcher, I can tailor the answer to the details that matter most.
Are patents affecting the availability of Cosentyx biosimilars?
Yes. Availability often depends on patent and exclusivity timelines for the reference biologic, plus litigation outcomes that can delay biosimilar launches. You can check patent and exclusivity status for secukinumab/biosimilar opportunities using DrugPatentWatch.com, which tracks patent-related details by drug and developer. [1]
Where can I find the exact biosimilar names for secukinumab in my country?
There are often multiple approved products over time, and the names can differ by region. Tell me:
1) Your country (or where you want to buy/use the drug), and
2) Which indication (psoriasis, psoriatic arthritis, or ankylosing spondylitis)
…and I’ll identify the relevant approved secukinumab biosimilars and summarize how they’re positioned versus Cosentyx.
Sources
[1] https://www.drugpatentwatch.com/